Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 2
2018 1
2019 2
2020 3
2021 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Rodler E, et al. Lancet Oncol. 2023 Feb;24(2):162-174. doi: 10.1016/S1470-2045(22)00739-2. Epub 2023 Jan 6. Lancet Oncol. 2023. PMID: 36623515 Free PMC article. Clinical Trial.
Eligible patients aged 18 years or older had metastatic or recurrent triple-negative breast cancer or germline BRCA1/2-associated metastatic or recurrent breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to one line of chem …
Eligible patients aged 18 years or older had metastatic or recurrent triple-negative breast cancer or germline BRCA1/2-associated metastatic …
[Systemic treatment of bladder cancer].
Tamalunas A, Schulz GB, Rodler S, Apfelbeck M, Stief CG, Casuscelli J. Tamalunas A, et al. Urologe A. 2021 Feb;60(2):247-258. doi: 10.1007/s00120-020-01420-5. Urologe A. 2021. PMID: 33398384 Review. German.
Although immunotherapy has made great progress in recent years, palliative chemotherapy remains the gold standard in first-line treatment. The armamentarium is continuously evolving: systemic immunotherapy is currently being investigated in nonmuscle-invasive BC as well as …
Although immunotherapy has made great progress in recent years, palliative chemotherapy remains the gold standard in first-line treat …
Salvage cystectomy and ileal conduit urinary diversion as a last-line option for benign diseases-perioperative safety and postoperative health-related quality of life.
Volz Y, Eismann L, Pfitzinger PL, Jokisch JF, Schulz G, Rodler S, Buchner A, Schlenker B, Stief CG, Kretschmer A. Volz Y, et al. Neurourol Urodyn. 2021 Jun;40(5):1154-1164. doi: 10.1002/nau.24671. Epub 2021 May 3. Neurourol Urodyn. 2021. PMID: 33939196
AIMS: Radical cystectomy and urinary diversion impact various dimensions of patients' health-related-quality-of-life (HRQOL). Yet, less is known about salvage cystectomy as a last-line option for treatment-refractory benign diseases. Therefore, our aim is to provide HRQOL …
AIMS: Radical cystectomy and urinary diversion impact various dimensions of patients' health-related-quality-of-life (HRQOL). Yet, less is k …
Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
Rodler S, Apfelbeck M, Schulz GB, Ivanova T, Buchner A, Staehler M, Heinemann V, Stief C, Casuscelli J. Rodler S, et al. Eur Urol Focus. 2020 Sep 15;6(5):1097-1103. doi: 10.1016/j.euf.2020.05.010. Epub 2020 Jun 10. Eur Urol Focus. 2020. PMID: 32534969 Free PMC article.
Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear "red line" concerning changes in existing patient-physician relationships. ...
Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear "red line" concerning changes …
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Seattle Cancer Care Alliance Network Investigators; Specht J. Symonds L, et al. Clin Breast Cancer. 2019 Apr;19(2):e283-e296. doi: 10.1016/j.clbc.2018.12.008. Epub 2018 Dec 14. Clin Breast Cancer. 2019. PMID: 30737173 Free PMC article. Clinical Trial.
We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. PATIENTS AND METHODS: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizum …
We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic …
Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers.
Rodler S, Buchner A, Stief CG, Heinemann V, Staehler M, Casuscelli J. Rodler S, et al. Clin Genitourin Cancer. 2021 Feb;19(1):76-82.e6. doi: 10.1016/j.clgc.2020.03.018. Epub 2020 Apr 7. Clin Genitourin Cancer. 2021. PMID: 32527682
However, for the development of future health care applications, aspects such as patient age, gender, and therapy line need to be considered in uro-oncologic patients....
However, for the development of future health care applications, aspects such as patient age, gender, and therapy line need to be con …
Systemic therapy in primary angiosarcoma of the spleen.
Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Ferreira BP, et al. Rare Tumors. 2012 Oct 10;4(4):e55. doi: 10.4081/rt.2012.e55. Epub 2012 Nov 13. Rare Tumors. 2012. PMID: 23372919 Free PMC article.
She was treated with 4 cycles of weekly paclitaxel prior to metastatic resection and 4 cycles of the same drug in an adjuvant scenario, achieving a pathological complete response to treatment. She is alive and on third-line systemic therapy. The second patient was a male p …
She was treated with 4 cycles of weekly paclitaxel prior to metastatic resection and 4 cycles of the same drug in an adjuvant scenario, achi …
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz GB, Todorova R, Braunschweig T, Rodler S, Volz Y, Eismann L, Pfitzinger P, Jokisch F, Buchner A, Stief C, Mayr D, Casuscelli J. Schulz GB, et al. Urol Oncol. 2021 Oct;39(10):734.e1-734.e10. doi: 10.1016/j.urolonc.2021.06.001. Epub 2021 Jul 11. Urol Oncol. 2021. PMID: 34261585
INTRODUCTION: For cisplatin-ineligible patients, approval of first-line immune-checkpoint inhibitor therapy relies on the programmed death ligand 1 (PD-L1) expression assay employed, namely, the combined positive score (CPS) or immune cell (IC) score. ...The findings highl …
INTRODUCTION: For cisplatin-ineligible patients, approval of first-line immune-checkpoint inhibitor therapy relies on the programmed …
Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.
Schlemmer M, Spek A, Rodler S, Schott M, Casuscelli J, Staehler M. Schlemmer M, et al. Cureus. 2019 Mar 13;11(3):e4244. doi: 10.7759/cureus.4244. Cureus. 2019. PMID: 31131167 Free PMC article.
Progression-free survival (PFS) for patients with first-line sorafenib was 11.6 months and was 8.7 months for sunitinib. ...No new safety signals were detected. CONCLUSION: None of the therapeutic first-line approaches was superior to the other. Sequencing tyrosine …
Progression-free survival (PFS) for patients with first-line sorafenib was 11.6 months and was 8.7 months for sunitinib. ...No new sa …
14 results